SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,425,212 | -13.3% | 2,715,235 | +25.0% | 1.86% | +5.2% |
| Q2 2023 | $45,469,106 | +10.6% | 2,172,437 | +11.6% | 1.76% | -2.8% |
| Q1 2023 | $41,113,290 | -11.0% | 1,946,652 | +7.3% | 1.82% | +9.8% |
| Q4 2022 | $46,182,435 | +49.1% | 1,814,634 | +40.8% | 1.65% | +47.5% |
| Q3 2022 | $30,976,000 | +177.2% | 1,289,073 | +122.0% | 1.12% | +163.1% |
| Q2 2022 | $11,174,000 | -68.5% | 580,768 | -71.6% | 0.43% | -67.9% |
| Q1 2022 | $35,514,000 | -22.9% | 2,043,377 | -2.9% | 1.33% | -15.3% |
| Q4 2021 | $46,046,000 | +29.8% | 2,103,512 | +13.3% | 1.57% | +50.3% |
| Q3 2021 | $35,482,000 | -3.7% | 1,856,738 | -13.4% | 1.04% | -9.6% |
| Q2 2021 | $36,828,000 | +11.0% | 2,144,881 | +44.5% | 1.15% | +13.9% |
| Q1 2021 | $33,187,000 | – | 1,484,227 | – | 1.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |